Ad Hoc: License costs: Increased license costs for extended ZEI trademark utilization rights

JENA/Germany, 27.03.2013.

Use of the "ZEISS" trademark is of great value to the company with regard to market profile and customer awareness. With effect from 1.10.13 Carl Zeiss Meditec AG and Carl Zeiss AG will therefore conclude a new trademark license agreement which secures the longer-term use of the "ZEISS" trademark for the entire product portfolio. The existing agreement only covered compensation for trademark utilization of some of the Carl Zeiss Meditec products. Due to the fact that the agreement could be cancelled at short notice this only provided Carl Zeiss Meditec with insufficient security for utilization of the trademark rights. The new agreement covers a period of three years and includes an extension option. The agreed compensation has been extended to cover sales of all products; this will result in higher costs for the company from the 2013/14 financial year. In comparison to the existing agreement which runs until 30.9.13 (annual costs: EUR 3.4 million), the new agreement would entail an increase of approximately EUR 4.3 million on the 2012/13 licensing costs figure.

Jann Gerrit Ohlendorf

Director Corporate Communications

Carl Zeiss Meditec AG

Phone: +49 3641 220-331

Fax: +49 3641 220-332

E-Mail:

press.meditec@zeiss.com

Henriette Meyer

Director Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-106

Fax:

E-Mail:

investors.meditec@zeiss.com

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. Carl Zeiss Meditecs medical technology portfolio is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2011/12 (ended 30 September) the companys around 2,400 employees generated revenue of just under EUR 862 million. Carl Zeiss Meditec headquarters are located in Jena, Germany.

The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, strengthen the companys presence in these fast-growing countries. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65% are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries. In the markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics, Carl Zeiss has contributed to technological progress for more than 160 years and enhances the quality of life of many people around the globe. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

For more information please go to: www.meditec.zeiss.com

Number: 0051-2013-ENG OP

Number of Words: 185

Number of Characters: 1242

LINK:	http://applications.zeiss.com/C1256A770030BCE0/WebViewTopNewsAllE/77F3...
	See more stories from zeiss

Most recent headlines